Efficacy of bevacizumab therapy for unresectable malignant glioma: A retrospective analysis

Yonezawa,Hajime; Hirano,Hirofumi; Uchida,Hiroyuki; Habu,Mika; Hanaya,Ryosuke; Oyoshi,Tatsuki; Sadamura,Yuko; Hanada,Tomoko; Tokimura,Hiroshi; Moinuddin,Fm; Arita,Kazunori

doi:10.3892/mco.2016.1086

January-2017 Volume 6 Issue 1

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

January-2017 Volume 6 Issue 1

Full Size Image

Article

Efficacy of bevacizumab therapy for unresectable malignant glioma: A retrospective analysis

Authors:
- Hajime Yonezawa
- Hirofumi Hirano
- Hiroyuki Uchida
- Mika Habu
- Ryosuke Hanaya
- Tatsuki Oyoshi
- Yuko Sadamura
- Tomoko Hanada
- Hiroshi Tokimura
- Fm Moinuddin
- Kazunori Arita
View Affiliations / Copyright

Affiliations: Department of Neurosurgery, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima 890‑8520, Japan
Pages: 105-110
|
Published online on: November 18, 2016

https://doi.org/10.3892/mco.2016.1086
Expand metrics +

Abstract

Bevacizumab (BEV), an inhibitor of vascular endothelial growth factor A, has been used for primary and recurrent malignant gliomas in Japan since June, 2013. Previous randomized controlled studies demonstrated that BEV prolonged the progression‑free survival, but not the overall survival (OS) of patients with newly diagnosed glioblastoma. The aim of the present study was to elucidate the effect of BEV on the OS of patients with unresectable malignant gliomas. Of the 440 cases of malignant glioma initially treated in our institute between 2000 and 2015, 88 were not suitable for maximal resection due to patient age, physical condition, tumor location and extent, or the patient's wishes. Based on the biopsy results, the pathological diagnosis was glioblastoma, anaplastic astrocytoma and anaplastic oligodendroglioma in 60, 19 and 9 patients, respectively. Kaplan‑Meier and log‑rank analyses were performed to investigate the effect of BEV on OS. OS was longer in the BEV group (n=24) compared with that in the non-BEV group [n=64; median survival time (MST), 566 vs. 243 days, respectively; hazard ratio (HR)=0.413; 95% confidence interval (CI): 0.216‑0.787; P=0.003]. In the 41 patients who received temozolomide (TMZ) and radiotherapy and the 31 patients with glioblastoma who received TMZ and radiotherapy, OS was longer in the BEV group compared with that in the non‑BEV group (MST, 568 vs. 334 days, HR=0.404, 95% CI: 0.175‑0.933, P=0.016; and MST, 566 vs. 160 days, HR=0.253, 95% CI: 0.099‑0.646, P=0.001, respectively). In the Cox hazard model analysis of 41 patients who underwent TMZ‑based chemoradiotherapy after biopsy, the use of BEV was the strongest independent beneficial factor associated with prolonged OS (HR=0.101; P=0.0002). Our retrospective survey suggested that BEV prolongs the OS of patients with unresectable malignant gliomas. However, these results must be verified by a well-designed prospective randomized controlled trial.

View Figures

View References

1	Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea D, et al: Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med. 370:709–722. 2014. View Article : Google Scholar : PubMed/NCBI
2	Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M, et al: A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 370:699–708. 2014. View Article : Google Scholar : PubMed/NCBI
3	Sandmann T, Bourgon R, Garcia J, Li C, Cloughesy T, Chinot OL, Wick W, Nishikawa R, Mason W, Henriksson R, et al: Patients with proneural glioblastoma may derive overall survival benefit from the addition of bevacizumab to first-line radiotherapy and temozolomide: Retrospective analysis of the AVAglio trial. J Clin Oncol. 33:2735–2744. 2015. View Article : Google Scholar : PubMed/NCBI
4	Sanai N, Polley MY, McDermott MW, Parsa AT and Berger MS: An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg. 115:3–8. 2011. View Article : Google Scholar : PubMed/NCBI
5	Kawano H, Hirano H, Yonezawa H, Yunoue S, Yatsushiro K, Ogita M, Hiraki Y, Uchida H, Habu M, Fujio S, et al: Improvement in treatment results of glioblastoma over the last three decades and beneficial factors. Br J Neurosurg. 29:206–212. 2015. View Article : Google Scholar : PubMed/NCBI
6	Committee of Brain Tumor Registry of Japan, . Report of Brain Tumor Registry of Japan (2001–2004). 13th ed. Neurol Med Chir (Tokyo). 54:(Suppl). 1–102. 2014.
7	Ferrara N, Hillan KJ and Novotny W: Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun. 333:328–335. 2005. View Article : Google Scholar : PubMed/NCBI
8	Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS and Ferrara N: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 362:841–844. 1993. View Article : Google Scholar : PubMed/NCBI
9	Mathieu V, De Nève N, Le Mercier M, Dewelle J, Gaussin JF, Dehoux M, Kiss R and Lefranc F: Combining bevacizumab with temozolomide increases the antitumor efficacy of temozolomide in a human glioblastoma orthotopic xenograft model. Neoplasia. 10:1383–1392. 2008. View Article : Google Scholar : PubMed/NCBI
10	Ebos JM and Kerbel RS: Antiangiogenic therapy: Impact on invasion, disease progression and metastasis. Nat Rev Clin Oncol. 8:210–221. 2011. View Article : Google Scholar : PubMed/NCBI
11	Ocaña A, Amir E, Vera F, Eisenhauer EA and Tannock IF: Addition of bevacizumab to chemotherapy for treatment of solid tumors: Similar results but different conclusions. J Clin Oncol. 29:254–256. 2011. View Article : Google Scholar
12	Amit L, Ben-Aharon I, Vidal L, Leibovici L and Stemmer S: The impact of bevacizumab (avastin) on survival in metastatic solid tumors-a meta-analysis and systematic review. PLoS One. 8:e517802013. View Article : Google Scholar : PubMed/NCBI
13	Li Q, Yan H, Zhao P, Yang Y and Cao B: Efficacy and safety of bevacizumab combined with chemotherapy for managing metastatic breast cancer: A meta-analysis of randomized controlled trials. Sci Rep. 5:157462015. View Article : Google Scholar : PubMed/NCBI
14	Broglio KR and Berry DA: Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst. 101:1642–1649. 2009. View Article : Google Scholar : PubMed/NCBI
15	Morita S, Sakamaki K and Yin G: Detecting overall survival benefit derived from survival postprogression rather than progression-free survival. J Natl Cancer Inst. 107:djv1332015. View Article : Google Scholar : PubMed/NCBI
16	Narita Y: Bevacizumab for glioblastoma. Ther Clin Risk Manag. 11:1759–1765. 2015. View Article : Google Scholar : PubMed/NCBI
17	Chauffer B, Feuvret L, Bonnetain F, Taillandier L, Frappaz D, Taillia H, Schott R, Honnorat J, Fabbro M, Tennevet I, et al: Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: Final results of the TEMAVIR study from ANOCEF. Ann Oncol. 25:1442–1447. 2014. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Efficacy of bevacizumab therapy for unresectable malignant glioma: A retrospective analysis

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Figure 4

Related Articles